Literature DB >> 17379162

Neutropenia: etiology and pathogenesis.

Lee S Schwartzberg1.   

Abstract

Neutropenia is defined as an absolute neutrophil count <1500 cells/mm(3) and can be graded as mild (1000-1500 cells/mm(3)), moderate (500-1000 cells/mm(3)), or severe (<500 cells/mm(3)). Neutropenia can develop as a result of > or =1 pathologic mechanism, including decreased bone marrow production, the sequestering of neutrophils, and increased destruction of neutrophils in the peripheral blood. The clinical result is increased risk for infection. This risk is directly proportional to the severity and duration of neutropenia. Neutropenia is classified according to the etiology as congenital or acquired, with the latter further defined according to the etiology or pathology. Febrile neutropenia is associated with substantial morbidity and even mortality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17379162     DOI: 10.1016/s1098-3597(06)80053-0

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  14 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Clinical pathologic conference case 5: agranulocytosis.

Authors:  Z B Kurago; A R Kerr; N Narayana
Journal:  Head Neck Pathol       Date:  2011-08-31

3.  Monitoring Neutropenia for Cancer Patients at the Point of Care.

Authors:  Hakan Inan; James L Kingsley; Mehmet O Ozen; Huseyin Cumhur Tekin; Christian R Hoerner; Yoriko Imae; Thomas J Metzner; Jordan S Preiss; Naside Gozde Durmus; Mehmet Ozsoz; Heather Wakelee; Alice C Fan; Erkan Tüzel; Utkan Demirci
Journal:  Small Methods       Date:  2017-08-09

4.  Hematologic impact of antibiotic administration on patients taking clozapine.

Authors:  Michael Shuman; Tammie Lee Demler; Eileen Trigoboff; Lewis A Opler
Journal:  Innov Clin Neurosci       Date:  2012-11

Review 5.  Concise review: next-generation cell therapies to prevent infections in neutropenic patients.

Authors:  Marion E G Brunck; Lars K Nielsen
Journal:  Stem Cells Transl Med       Date:  2014-03-05       Impact factor: 6.940

6.  Quantitative Simulations Predict Treatment Strategies Against Fungal Infections in Virtual Neutropenic Patients.

Authors:  Sandra Timme; Teresa Lehnert; Maria T E Prauße; Kerstin Hünniger; Ines Leonhardt; Oliver Kurzai; Marc Thilo Figge
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

7.  Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome.

Authors:  George E Fragoulis; Caron Paterson; Ashley Gilmour; Mohammad H Derakhshan; Iain B McInnes; Duncan Porter; Stefan Siebert
Journal:  RMD Open       Date:  2018-10-08

8.  Network mapping of primary CD34+ cells by Ampliseq based whole transcriptome targeted resequencing identifies unexplored differentiation regulatory relationships.

Authors:  Jessica L Schwaber; Darren Korbie; Stacey Andersen; Erica Lin; Panagiotis K Chrysanthopoulos; Matt Trau; Lars K Nielsen
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

9.  Influenza in hospitalised patients with malignancy: a propensity score matching analysis.

Authors:  Jiarui Li; Dingding Zhang; Zhao Sun; Chunmei Bai; Lin Zhao
Journal:  ESMO Open       Date:  2020-10

10.  Austrian syndrome, ceftriaxone-induced agranulocytosis and COVID-19.

Authors:  James Edward McCulloch; Alexandra Miller; Marius Borcea; Jeremy Reid
Journal:  BMJ Case Rep       Date:  2021-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.